Tildrakizumab治疗斑块状银屑病:持续给药、中断治疗、剂量调整及从依那西普转换的疗效与安全性
基于reSURFACE研究(N=1862)的亚组分析,评估tildrakizumab在持续给药、剂量调整、中断后重启及从依那西普转换等场景下的疗效与安全性。结果显示部分应答者继续治疗或调整剂量后PASI 75应答随时间提升,中断后重启多数可再获PASI 75,从依那西普转换后应答亦提高,治疗耐受性良好。
要点
- 持续或调整剂量治疗可提高部分应答者的PASI 75应答率
- 中断治疗后重启tildrakizumab,多数患者可重新达到PASI 75
- 从依那西普转换至tildrakizumab后PASI 75应答显著提升
核心结论
- 斑块状银屑病患者接受tildrakizumab维持、重启、剂量调整或起始治疗总体耐受良好且有效。
研究设计与样本
- 基于reSURFACE III期研究(N=1862)的亚组分析,纳入第3部分(第28-52周或第64周)的应答者(PASI≥75%)和部分应答者(PASI≥50%且<75%)。
- 患者接受tildrakizumab 200 mg或100 mg后被重新随机分配至相同剂量、更高/更低剂量或安慰剂;安慰剂组复发后重启tildrakizumab;依那西普第28周部分应答或无应答者(PASI<50%)接受tildrakizumab 200 mg。
主要发现
- T100/T100和T200/T200第28周部分应答者中,达到PASI 75应答的比例随时间增加。
- T100/PBO和T200/PBO组复发后重启tildrakizumab的患者中,分别有86%和83%在第64周达到PASI 75。
- PASI 90、PASI 100和医生整体评估应答与PASI 75结果一致;治疗耐受性良好。
临床怎么用
- 对于部分应答者,可考虑维持原剂量、调整剂量或中断后重启tildrakizumab以提升应答。
- 从依那西普转换至tildrakizumab 200 mg可为部分应答或无应答者带来额外获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic psoriasis may require medication adjustments over time. OBJECTIVES: To evaluate the efficacy/safety of tildrakizumab in subgroups from the reSURFACE studies (N = 1862) that received continuous dosing, higher/lower dosing, treatment interruption/reinitiation and initiation. METHODS: Responders [Psoriasis Area and Severity Index (PASI) ≥ 75%] and partial responders (PASI ≥ 50% to < 75%) in Part 3 of the reSURFACE studies (weeks 28-52 or week 64) who received tildrakizumab 200 mg or 100 mg were rerandomized to the same dosage (T100/T100 or T200/T200), a higher/lower dosage (T100/T200 or T200/T100) or placebo (PBO) (T100/PBO or T200/PBO). Patients receiving PBO who relapsed were reinitiated to tildrakizumab. Etanercept (ETN) week-28 partial responders and nonresponders (PASI < 50%) received tildrakizumab 200 mg (ETN/T200). RESULTS: Among T100/T100 and T200/T200 week-28 partial responders, the proportion of patients who achieved as-observed PASI 75 responses increased over time. Among T100/T200 week-28 partial responders, PASI 75 responses increased from week 32 (38·5%) to week 52 (63·2%) and remained consistent in T200/T100 week-28 responders. Among patients who relapsed in the T100/PBO and T200/PBO groups, 86% and 83% of those who reinitiated tildrakizumab achieved PASI 75 by week 64, respectively. Among ETN/T200 week-28 partial responders, PASI 75 responses (nonresponder imputation) increased from week 32 (24·1%) to week 52 (74·7%). PASI 90, PASI 100 and Physician's Global Assessment responses were consistent with PASI 75 results. Treatment was well tolerated. CONCLUSIONS: Patients generally fared well with tildrakizumab maintenance, reinitiation, dose adjustment or initiation. What's already known about this topic? Tildrakizumab demonstrated significant efficacy vs. placebo with a positive safety profile during the first 28 weeks of treatment in two randomized double-blind trials. What does this study add? Treatment scenarios with tildrakizumab, such as long-term continuous dosing (up to 64 weeks), treatment interruption/reinitiation and switching from another biologic, can be part of the management of plaque psoriasis with a reasonable expectation of efficacy and tolerability.
引用
- Kimball AB, Papp KA, Reich K, et al. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. Br J Dermatol. 2019. PMID: 31487406. doi:10.1111/bjd.18484
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。